Use of bumetanide in the treatment of ascites due to liver disease.
Bumetanide is an effective diuretic for the treatment of ascites. Fifteen out of 17 patients with chronic liver disease responded satisfactorily and the incidence of hepatic encephalopathy and electrolyte disturbances was similar to that previously observed with frusemide. Colicky abdominal pain was reported in three patients but no other adverse effects were noted. An unexpected response was obtained in two patients who had diuresis without natriuresis.
D000293:Adolescent; D000328:Adult; D000368:Aged; D001201:Ascites / Q000178:diet therapy / Q000188:drug therapy* / Q000209:etiology; D001565:Benzoates / Q000627:therapeutic use*; D001663:Bilirubin / Q000097:blood; D001786:Blood Glucose / Q000032:analysis; D001835:Body Weight; D002082:Butylamines / Q000627:therapeutic use; D002908:Chronic Disease; D004232:Diuretics / Q000627:therapeutic use*; D005260:Female; D006501:Hepatic Encephalopathy / Q000188:drug therapy; D006801:Humans; D008107:Liver Diseases / Q000150:complications / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009318:Natriuresis / Q000187:drug effects; D010647:Phenyl Ethers / Q000627:therapeutic use; D011188:Potassium / Q000097:blood; D012964:Sodium / Q000097:blood; D013449:Sulfonamides; D014508:Urea / Q000097:blood
D001565:Benzoates; D001786:Blood Glucose; D002082:Butylamines; D004232:Diuretics; D010647:Phenyl Ethers; D013449:Sulfonamides; D014508:Urea; D012964:Sodium; D001663:Bilirubin; D011188:Potassium